[1] 全国卫生产业企业管理协会妇幼健康产业分会生殖内分泌学组. 中国子宫内膜增生诊疗共识[J]. 生殖医学杂志, 2017,26(10):957-910. [2] Kuramn R J,Jaminski P F,Norris H J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients[J]. Cancer,1985,56:403-412. [3] Emons G,Beckmann M,Schmidt D,et al. New WHO classification of endometrial hyperplasias[J]. Geburtshil Frauenheilkund,2015,75(2):135-136. [4] Mccausland A M,Mccausland V M. Long-term clinical outcomes following resectoscopic endometrial ablation of non-atypical endometrial hyperplasia in women with abnormal uterine bleeding[J]. J Minimall Invasive Gynecol,2015,22(4):703-704. [5] Graul A,Wilson E,Ko E,et al. Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients[J]. Gynecol Oncol Rep,2018,26:45-48. [6] Abu Hashim H,Ghayaty E,El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia:a systematic review and metaanalysis of randomized trials[J]. Am J Obstetr Gynecol,2015,213(4):469-478. [7] Hemida R A,Zayed A E,Shalaby A,et al. Agreement of histopathological findings of preoperative uterine curettage and hysterectomy specimens:Impact of time factor and hormonal therapy[J]. J Exp Therapeut Oncol,2013,10(3):165-168. [8] Al Nemer A M,Al Bayat M I,Al Qahtani N H. The accuracy of endometrial sampling for the diagnosis of patterns of endometrial pathology in women presenting with abnormal uterine bleeding. More conservative therapeutic approaches[J]. Saudi Med J,2019, 40(8):815-819. |